论文部分内容阅读
背景:有研究显示川芎嗪160mg/L抑制体外培养的内皮细胞生长,但其是否能抑制血管内皮生长因子诱导的血管内皮细胞的增殖报道较少。目的:探讨川芎嗪含药血清对血管内皮细胞和对血管内皮生长因子诱导的血管内皮细胞增殖的影响。设计:随机对照实验。单位:重庆医科大学中医药学院。材料:实验于2002-03/2003-03在重庆医科大学儿科研究所完成。选用人脐静脉内皮细胞系ECV304;Wistar雌性大鼠30只。方法:30只大鼠随机分为3组,每组10只,川芎嗪143.0mg/kg组,川芎嗪71.5mg/kg组,分别于腹腔注射相应剂量川芎嗪,每组分别设血清浓度20%,10%,5%3组,各组均设重复孔3个。空白对照组10只予腹腔注射0.8mL生理盐水。均1次/d,连续7d后从腹主动脉取血。川芎嗪含药血清对细胞增殖的作用观察采用体外培养技术以及3H胸腺嘧啶核苷掺入法和四氮唑蓝法检测。主要观察指标:①川芎嗪含药血清对人脐静脉内皮细胞系ECV304细胞增殖的影响。②川芎嗪动物血清对血管内皮生长因子诱导的人脐静脉内皮细胞系ECV304细胞增殖的影响。结果:进入结果分析的大鼠为30只,无缺失值。①川芎嗪含药血清对人脐静脉内皮细胞系ECV304细胞增殖的影响:血清浓度分别为5%10%,20%的川芎嗪143.0mg/kg组,其吸光度(A)值、放射性核素闪烁计数(min-1)较对照组显著减少犤5%:0.720±0.024,0.816±0.068;3340.45±567.75120.84±301.49;10%:0.630±0.017,0.798±0.015;2430.06±265.985225.83±100.10,20%:0.765±0.027,0.823±0.031;3570.45±130.525256.82±183.18犦。血清浓度分别为10%,20%的川芎嗪71.5mg/kg组其吸光度(A)值、放射性核素闪烁计数(min-1)较对照组显著减少犤10%0.775±0.023,0.798±0.015;4571.14±275.39,5225.83±100.10,20%0.749±0.012,0.823±0.031;3287.25±144.82,5256.82±183.18犦。②川芎嗪动物血清对血管内皮生长因子诱导的人脐静脉内皮细胞系ECV304细胞增殖的影响:血清浓度分别为5%,10%,20%的川芎嗪143.0mg/k组,其吸光度(A)值、放射性核素闪烁计数(min-1)较对照组显著减少犤5%:0.726±0.004,0.964±0.004;5760.46±49.64,9821.82±128.0510%:0.712±0.004,0.933±0.014;5024.48±100.57,9052.76±65.19;20%0.717±0.003,0.924±0.004;5405.45±140.90,9197.07±169.92犦。血清浓度分别为10%,20%的川芎嗪71.5mg/kg组,其吸光度(A)值、放射性核素闪烁计数(min-1)较对照组显著减少犤10%:0.703±0.005,0.933±0.0147526.47±169.21,9052.76±65.19;20%:0.693±0.006,0.924±0.0045720.09±279.03,9197.07±169.92犦。结论:川芎嗪143mg/kg动物血清浓度5%,10%,20%;71.5mg/kg动物血清高浓度对ECV304细胞增殖有显著的抑制作用。川芎嗪143mg/k动物血清3种浓度;川芎嗪71.5mg/kg动物血清20%,10%对血管内皮生长因子诱导的ECV304细胞增殖有显著的抑制作用。
BACKGROUND: Studies have shown that tetramethylpyrazine 160mg/L inhibits the growth of endothelial cells in vitro, but it is less reported whether it can inhibit vascular endothelial growth factor-induced proliferation of vascular endothelial cells. Objective: To investigate the effect of Ligustrazine-containing serum on vascular endothelial cells and vascular endothelial growth factor-induced proliferation of vascular endothelial cells. Design: Randomized controlled trials. Unit: School of Traditional Chinese Medicine, Chongqing Medical University. MATERIALS: The experiment was performed at the Institute of Pediatrics, Chongqing Medical University from March 2002 to March 2003. Human umbilical vein endothelial cell line ECV304 was selected; 30 female Wistar rats were used. METHODS: Thirty rats were randomly divided into 3 groups, 10 in each group, 143.0 mg/kg of tetramethylpyrazine and 71.5 mg/kg of tetramethylpyrazine. The corresponding doses of tetramethylpyrazine were injected intraperitoneally, and the serum concentration was set at 20% in each group. , 10%, 5% 3 groups, each group has set up 3 duplicate holes. In the blank control group, 10 rats were intraperitoneally injected with 0.8 mL physiological saline. Once a day, blood was taken from the abdominal aorta 7 days afterwards. The effect of tetramethylpyrazine-containing serum on cell proliferation was observed by in vitro culture technique and 3H thymidine incorporation assay and tetrazolium blue assay. MAIN OUTCOME MEASURES: The effect of Ligustrazine-containing serum on the proliferation of human umbilical vein endothelial cell ECV304 cells. 2 The effects of ligustrazine animal serum on the proliferation of human umbilical vein endothelial cell ECV304 cells induced by vascular endothelial growth factor. RESULTS: Thirty rats were included in the analysis of the results and no missing values were found. 1 The effect of Ligustrazine-containing serum on the proliferation of human umbilical vein endothelial cell line ECV304: serum concentration of 5% 10%, 20% tetramethylpyrazine 143.0mg/kg group, absorbance (A) value, radionuclide scintillation The count (min-1) was significantly reduced by 5% compared to the control group: 0.720±0.024, 0.816±0.068; 3340.45±567.75120.84±301.49; 10%: 0.630±0.017, 0.798±0.015; 2430.06±265.985225.83±100.10. 20%: 0.765 ± 0.027, 0.823 ± 0.031; 3570.45 ± 130.525256.82 ± 183.18 inches. The serum concentration was 10%, and the absorbance (A) value and radionuclide scintillation count (min-1) of 20% Ligustrazine 71.5mg/kg group were significantly decreased by 犤10% 0.775±0.023, 0.798±0.015 compared with the control group; 4571.14±275.39, 5225.83±100.10, 20% 0.749±0.012, 0.823±0.031; 3287.25±144.82, 5258.82±183.18 inches. 2 Ligustrazine animal serum on vascular endothelial growth factor-induced proliferation of human umbilical vein endothelial cell line ECV304 cells: serum concentrations of 5%, 10%, 20% tetramethylpyrazine 143.0mg / k group, the absorbance (A) Values and radionuclide scintillation counts (min-1) were significantly reduced by 5% compared with the control group: 0.726±0.004, 0.964±0.004; 5760.46±49.64, 9821.82±128.0510%: 0.712±0.004, 0.933±0.014; 5024.48±100.57, 9052.76 ± 65.19; 20% 0.717 ± 0.003, 0.924 ± 0.004; 5405.45 ± 140.90, 9197.07 ± 169.92 Torr. Serum concentrations of 10% and 20% of Ligustrazine 71.5mg/kg group, respectively, its absorbance (A) value, radionuclide scintillation count (min-1) significantly reduced compared to the control group 犤10%: 0.703 ± 0.005, 0.933 ± 0.0147526.47±169.21,9052.76±65.19; 20%: 0.693±0.006, 0.924±0.0045720.09±279.03, 9197.07±169.92犦. Conclusion: The serum concentration of tetramethylpyrazine 143mg/kg animals is 5%, 10%, 20%; 71.5mg/kg animal serum high concentration has a significant inhibitory effect on the proliferation of ECV304 cells. Ligustrazine 143mg/k animal serum three concentrations; Ligustrazine 71.5mg/kg animal serum 20%, 10% on vascular endothelial growth factor-induced proliferation of ECV304 cells have a significant inhibitory effect.